Latest
Yahoo finance API is not available right now, please try again soon...

Articles by admin

Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel’s Ministry of Health has granted the Company approval to initiate an exploratory clinical study of its oral insulin capsule ORMD-0801 in patients with nonalcoholic steatohepatitis (NASH). The proposed three-month treatment study will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH. Oramed plans on initiating the study in the coming month. “Data from our directed preclinical NASH studies and clinical studies of ORMD-0801 in diabetics has revealed, through exploratory endpoints, that our oral insulin capsule has the ability to reduce inflammation of the liver. Incidence of NASH is rapidly increasing, similar to the rates of increase in diabetes. We look forward to exploring ORMD-0801 as a potential treatment for NASH,” stated Oramed CEO, Nadav Kidron. About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

Host Annamaria Stewart gives viewers a look behind the scenes of the Macy’s Thanksgiving Day Parade starting with the Macy’s Parade Studio; a 72,000 square foot warehouse where the creative minds behind the Macy’s Thanksgiving Day Parade work year-round to conceptualize, design, and bring to life the 26 floats, 4,200 costumes, and 17 character balloons viewed by over 50 million people on Thanksgiving morning. She then heads to Balloonfest at MetLife Stadium, where all of the parade’s new Giant Character Balloons make a pit stop for a test flight alongside their flight management crews and handlers.

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

This series is part of the Huffington Post Outspeak Network.

In the age of Netflix, it takes more than a box of Milk Duds and a fountain soda to convince New Yorkers to leave their homes to catch a flick. Host Annamaria Stewart breaks down our picks for the coolest movie theaters in NYC, giving you four reasons to leave your bed and head to the big screen. These next level cinemas have pulled out all the stops, from sky scraping views to choreographed menus, and seatside filet. So sit back, relax, and enjoy the show. 1. Nitehawk Cinema 2. Metrograph 3. Rooftop Cinema Club 4. iPic Theaters This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers. This series is part of the Huffington Post Outspeak Network.

US Open Ballperson: Making the Cut

August 14, 2017 // 0 Comments

Every year crowds flock to the USTA Billie Jean King National Tennis Center to attend the US Open. But months before the players arrive nearly 500 people swarm the courts vying for only 80 coveted spots as one of the tournament’s official ballpersons. After some inside tips from the Director of US Open Ballpersons, Tina Taps, host Annamaria Stewart goes through the rigorous tryout process with Cathie Delaney, Assistant Director of US Open Ballpersons, to see if she has what it takes to be a ballperson at the US Open.

Ballperson Credits:
Hudson Kaylie – 4 year US Open Veteran
Wesley Chu – 13 year US Open Veteran
Justin Holmes – 5 year US Open Veteran

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

Pluristem has announced its pivotal Phase III clinical trial to treat critical limb ischemia received clearance from regulatory authorities in the United States, United Kingdom and Germany. Based on these clearances, the Company expects to begin enrolling patients in this study in the coming months.

Pluristem’s PLX-PAD cells will be evaluated in a double blind, randomized, placebo controlled trial in 250 patients.

The global market for treating critical limb ischemia is $12 billion globally. 1.7 million patients who live in world’s largest and most advanced pharmaceutical markets suffer from this limb-threatening and life-threatening disease. This number is expected to top 2 million in the next five years.

Pluristem’s critical limb ischemia program has been selected by the European Medicines Agency for its Adaptive Pathways pilot project. This allows for faster marketing approval in Europe after a single pivotal Phase III trial.

In the current Phase III trial, an interim analysis of data will be made for the first 125 patients, potentially leading to early marketing approval in Europe. Full enrollment is to be completed as planned to pursue full marketing approval in the U.S.

Regenerative medicines like PLX cells will have tremendous benefits on healthcare economics based on their efficacy and their non-invasive nature.

Can-Fite has reported that it is commencing patient recruitment in its global, pivotal Phase III trial of its lead drug candidate Piclidenoson in the treatment of rheumatoid arthritis.  The study, titled ACRobat, will enroll 500 patients in Europe, Israel and Canada.

The company reported drug supplies for trial have been manufactured and are ready for administration. The trial will have an estimated cost of $5 million, a modest cost when considering the global market for rheumatoid arthritis drugs is currently $38.5 billion.

Can-Fite’s drug is being developed as a first line therapy and replacement for the current standard of care, Methotrexate. Methotrexate is the most widely used drug for rheumatoid arthritis.

90% of rheumatoid arthritis patients receive Methotrexate at some point in their disease, but 40-50% of patients stop taking it after five years, due to its serious side-effects.

Over 1,000 patients have been safely treated with Piclidenoson, which has shown no series side effects and has proven to be safe. Piclidenoson can offer a superior alternative to Methotrexate for patients who need a safe and effective drug that can be taken long term.

You’ve seen it in movies and TV shows, but 3D replication is no longer a thing of the future. Host Annamaria Stewart stops by DOOB SoHo to step into their doob-licator full-body scanner and then heads to the company’s Brooklyn production facility to watch her custom action figure come to life through 3D printing.

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

This series is part of the Huffington Post Outspeak Network.

In 1862, Ladurée opened the doors to their first bakery in Paris, France. In 1930, the French patisserie invented what would become their signature item, the macaron. In 2011, Ladurée finally arrived stateside with their first US location on Madison Avenue and in 2014 they opened their first North American tea salon in SoHo. Now Ladurée is opening up their kitchen to teach fans how to make their best selling pastry, the Ispahan. Host Annamaria Stewart heads to Ladurée SoHo’s pastry kitchen for a lesson from Executive Pastry Chef Jimmy Leclerc.

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers

After 54 years and more than 20 studio albums, Exhibitionism – The Rolling Stones is finally giving fans the satisfaction they could never get, with a 17,000 square foot interactive exhibit packed with over 500 pieces of personal memorabilia, 190 original artworks, and 9 thematic galleries that are purely rock n’ roll. Host Annamaria Stewart speaks with Exhibitionism curator Ileen Gallagher about collaborating with the band members, The Stones’ iconic fashion, and recreating their Edith Grove flat.

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

This series is part of the Huffington Post Outspeak Network.

In 2016 consumers will use their mobile phones to spend a total of 620 billion dollars and analysts expect this number to grow to over 1 trillion dollars by 2020. Hoping to capitalize on consumers preference for convenient transactions new payment technologies such as peer to peer payments, crypto currencies and digital wallets have seen rapid growth. In this special report, Corporate Profile® delves into the future of cashless technology with Shlomi Cohen the CEO of OTI (On Track Innovations www.otiglobal.com), a company which hopes to further change the way consumers pay with wearable payment devices.

1 2 3 122